Prurigo Nodularis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

Prurigo Nodularis Companies are Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others.
(Albany, USA) DelveInsight's "Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Prurigo Nodularis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Prurigo Nodularis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Prurigo Nodularis market.

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast [https://www.delveinsight.com/report-store/prurigo-nodularis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Prurigo Nodularis Market Report:

* The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In March 2025, Incyte (Nasdaq:INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies - evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura Registered ), a topical JAK1/2 inhibitor, in adult patients ( greater than or equal to 18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 - Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7-11, 2025, in Orlando.
* In February 2025, Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab's subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at least 30kg, who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
* In August 2024, Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio Registered (nemolizumab) as a pre-filled pen for subcutaneous injection to treat adults with prurigo nodularis. Nemluvio received Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024, highlighting its potential to significantly enhance treatment for serious conditions.
* In March 2024, Incyte revealed recently released late-breaking data from a Phase II study assessing povorcitinib in individuals diagnosed with prurigo nodularis.
* According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients.
* In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis.
* DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development.
* Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
* Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
* The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis
* The Prurigo Nodularis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

Prurigo Nodularis Overview

Prurigo Nodularis (PN) is a chronic inflammatory skin disorder characterized by the presence of multiple, intensely itchy, firm nodules that develop due to prolonged scratching and skin trauma. The exact cause of Prurigo Nodularis remains unclear, but it is associated with immune system dysregulation, chronic pruritus, nerve abnormalities, and underlying conditions such as atopic dermatitis, diabetes, chronic kidney disease, HIV, and psychiatric disorders.

Prurigo Nodularis Patients experience severe, persistent pruritus (itching), often leading to excoriated, hyperpigmented, or lichenified nodules that typically affect the arms, legs, and trunk. The itch-scratch cycle worsens the condition, making it difficult to treat. Prurigo Nodularis significantly impacts quality of life, causing sleep disturbances, anxiety, depression, and social embarrassment.

Prurigo Nodularis Diagnosis is clinical, based on the characteristic nodules and patient history, but may require skin biopsies, blood tests, or nerve function assessments to rule out underlying conditions. Treatment focuses on breaking the itch-scratch cycle using topical corticosteroids, calcineurin inhibitors, antihistamines, and emollients. In severe cases, biologic therapies (such as IL-31 inhibitors), immunosuppressants, gabapentinoids, and phototherapy may be needed. Recent advancements in targeted biologics and neuromodulators are improving outcomes, offering new hope for long-term disease control and symptom relief in Prurigo Nodularis patients.

Get a Free sample for the Prurigo Nodularis Market Report: https://www.delveinsight.com/report-store/prurigo-nodularis-market [https://www.delveinsight.com/report-store/prurigo-nodularis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Prurigo Nodularis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Prurigo Nodularis
* Prevalent Cases of Prurigo Nodularis by severity
* Gender-specific Prevalence of Prurigo Nodularis
* Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast [https://www.delveinsight.com/sample-request/prurigo-nodularis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prurigo Nodularis Therapies and Key Companies

* Nalbuphine ER: Trevi Therapeutics
* Nemolizumab: Galderma
* Vixarelimab(KPL-716): Genentech
* Povorcitinib(INCB-54707): Incyte Corporation
* Ruxolitinib Cream: Incyte Corporation
* INCB054707: Incyte Corporation
* serlopitant: Vyne Therapeutics Inc.
* CC-10004: Celgene Corporation
* Pimecrolimus: Novartis
* Abrocitinib: Pfizer
* Dupilumab SAR231893: Regeneron Pharma

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market [https://www.delveinsight.com/sample-request/prurigo-nodularis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Prurigo Nodularis Market Strengths

Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options. Vixarelimab's dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

Prurigo Nodularis Market Opportunities

Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market. Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies.

Scope of the Prurigo Nodularis Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
* Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
* Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies
* Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Prurigo Nodularis Unmet Needs, KOL's views, Analyst's views, Prurigo Nodularis Market Access and Reimbursement

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/prurigo-nodularis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2020-2034)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17. Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prurigo-nodularis-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-nda-approvals-medication-prevalence-moa-revenue-statistics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.